MIRA Pharmaceuticals is an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a molecular synthetic tetrahydrocannabinol analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. The MIRA stock yearly return is shown above.
The yearly return on the MIRA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MIRA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|